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Abstract
Background: CYP2E1 encodes a member of the cytochrome P450 superfamily of enzymes which play a central
role in activating and detoxifying many carcinogens and endogenous compounds thought to be involved in the
development of cancer. The PstI/RsaI and DraI polymorphism are two of the most commonly studied
polymorphisms of the gene for their association with risk of head and neck cancer, but the results are conflicting.
Methods: We performed a meta-analysis using 21 eligible case-control studies with a total of 4,951 patients and
6,071 controls to summarize the data on the association between the CYP2E1 PstI/RsaI and DraI polymorphism and
head and neck cancer risk, especially by interacting with smoking or alcohol.
Results: Compared with the wild genotype, the OR was 1.96 (95% CI: 1.33-2.90) for PstI/RsaI and 1.56 (95% CI:
1.06-2.27) for DraI polymorphism respectively. When stratified according to ethnicity, the OR increased in the Asians
for both polymorphisms (OR = 2.04, 95% CI: 1.32-3.15 for PstI/RsaI; OR = 2.04, 95% CI: 1.27-3.29 for DraI), suggesting
that the risk is more pronounced in Asians.
Conclusion: Our meta-analysis suggests that individuals with the homozygote genotypes of PstI/RsaI or DraI
polymorphism might be associated with an increased risk of head and neck cancer, especially in Asians.
Background
Squamous cell carcinoma of head and neck (HNSCC),
including the oral cavity, pharynx, and larynx, is the sixth
most common cancer in the world [1]. Epidemiological
studies have shown that this type of cancer is one of those
most strongly related to environmental factors, such as
tobacco smoking and alcohol consumption. Many chemi-
cal carcinogens present in tobacco and alcohol undergo
metabolic activation by phase I enzymes, in particular the
cytochrome P450 (CYP). The activated metabolites are
subsequently subjected to other detoxification steps by
phase II enzymes such as glutathione S-transferases
(GSTs) and N-acetyltransferases (NATs). It is hypothe-
sized that part of the susceptibility to head and neck
cancer may be determined by the inter-individual dif-
ferences in the bioactivation of procarcinogens and
detoxification of carcinogens. CYP2E1,w h i c hi sam a j o r
component of the microsomal system involved in the
metabolism of ethanol and acetone among phase I
enzymes, has been widely studied as a cause of susceptibil-
ity to head and neck cancer [2,3].
The CYP2E1 gene, located on chromosome 10q26.3, is
constitutively expressed in human liver and is responsible
for the catalysis of xenobiotic. The protein encoded by
this gene specifically activates N-nitrosamines and ben-
zene, contained in cigarette smoke [4], and catalyses
molecular oxygen to active oxygen forms (e.g., superox-
ide anion radical, hydrogen peroxide, etc.), which lead to
intensified lipid and protein peroxidation, DNA damage,
and ultimately carcinogenesis [5]. Several functional poly-
morphisms have been reported for the CYP2E1 gene.
Two point mutations in the 5’-flanking region (PstI,
RsaI), which are in complete linkage disequilibrium, was
found to be associated with higher-transcription and
increased enzyme activity [6]. These mutations generate
the CYP2E1 wild (c1) allele and the less common (c2)
allele and have been reported as conferring higher risk
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any medium, provided the original work is properly cited.for developing oral, pharyngeal [7] and lung cancer [8].
Another important polymorphism detectable with DraI
in intron 6 is T7632A (rs6413432), a mutation of T to A,
which is reported to enhance transcription of the
CYP2E1 gene [9]. Polymorphisms in CYP2E1 are there-
fore believed to be risk factors for HNSCC.
A number of studies have investigated the associations
between CYP2E1 polymorphisms and HNSCC suscept-
ibility. However, these studies have yielded contradictory
results, with some studies showing a significant associa-
tion, while others showing no such association. Such
inconsistency could be due to the small effect of the
polymorphism on HNSCC risk and the relatively small
sample-size in each of the published studies. We there-
fore performed a meta-analysis of the published studies
to clarify this inconsistency and to establish a compre-
hensive picture of the relationship between CYP2E1 and
HNSCC.
Methods
Identification and eligibility of relevant studies
The literature included in the current analysis was
selected using PubMed with keywords “head and neck”
or “oral-neoplasms” or “larynx” or “pharynx” and “cancer”
or “carcinoma”, “HNSCC” or “SCCHN”, “cytochrome
p450 2E1/IIE1”, “polymorphism” or “variant” and abbre-
viations of the gene “Cyp2e1”. No other limits were used
during electronic search. All references cited in these stu-
dies and previously published review articles were
reviewed to identify additional work not indexed by
MEDLINE. The analyzed data is drawn from all English
language publications up to August 2009.
Only those studies assessing the association between
head and neck cancer and the CYP2E1 gene polymorph-
isms were included. Eligible studies had to meet the cri-
teria: (1) They were original papers containing
independent data, (2) identification of HNSCC was con-
firmed histologically or pathologically, (3) they provided
sufficient data to calculate the odds ratio (OR) or
P-value, (4) they used a case-control design, (5) they
described genotyping method, equipment and protocols
or made reference to them. The major reasons for exclu-
sion of studies were (1) they were family studies, (2) they
contained overlapping data, (3) they were review papers.
Quality assessment and data extraction
Each article was read and assessed according to the score
scale for randomized controlled association study pro-
posed by Dawei et al [10]. In brief, papers were rated
according to several items on the scale in relation to two
areas: experiment design to minimize potential bias and
data analysis. The quality score categorizes studies as of
“high’’ or ‘’low’’ quality.
For each study, the following information was
extracted independently by two investigators: first
author’s surname, publication date, diagnosis criterion,
gender, ethnicity, genotyping method, cigarette smok-
ing status, alcohol consumption, total number of cases
and controls and the numbers of cases and controls
with the three genotypes. The results were compared
and disagreements were discussed and resolved with
consensus. Where essential information was not pre-
sented in articles, every effort was made to contact the
authors.
Statistical analysis
For the control group of each study, the distributions of
genotypes were tested for Hardy-Weinberg equilibrium
(HWE) using the Chi-square test. If controls of studies
were found not to be in HWE, sensitivity analyses were
performed with and without these studies to test the
robustness of the findings. For the RsaI/PstI polymorph-
ism, we first estimated the risks of the c1c2 and c2c2
genotypes on HNSCC, compared with the wild-type
c1c1 homozygote. The risk of c1c2+c2c2 versus c1c1 on
cancers was then evaluated in dominant model. The
same evaluation was carried out for the DraI poly-
morphism. The strength of the association between the
CYP2E1 polymorphism and head and neck cancer risk
was measured by odds ratios (ORs) with 95% confidence
intervals (CIs).
Cochran’s c
2 based Q-statistic test [11,12] and I
2 -test
[13] were performed to assess possible heterogeneity in
the combined studies. If heterogeneity existed, the ran-
dom effects model (the DerSimonian and Laird method)
[14], which yields wider confidence intervals, was
adopted to calculate the overall OR value. Otherwise,
the fixed effects model (the Mantel-Haenszel method)
was used [15]. In addition, sources of heterogeneity
were investigated by stratified meta-analyses based on
ethnicity (Asian and Caucasian populations), quality
(high and low) of the studies, smoking status (ever/
never smokers) and alcohol consumption (users/non-
users). Asian populations are mainly composed of Chi-
nese and Japanese without Indian. 95% CIs were con-
structed using Woolf’s method [16]. The significance of
the overall OR was determined by the Z-test. Funnel
plots and Egger’s linear regression test were used to
assess evidence for potential publication bias [17]. In
order to assess the stability of the result, sensitivity ana-
lyses were performed, each study in turn was removed
from the total, and the remaining were reanalyzed. The
analysis was conducted using Comprehensive Meta Ana-
lysis software (Version 1.0.23, BIOSTAT, Englewood,
NJ). The type I error rate was set at 0.05. All P-values
were two-tailed.
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Characteristics of studies
Figure 1 shows the study selection process. The com-
bined search yielded 88 references. After discarding
overlapping references and those which clearly did not
meet the criteria, 24 studies were retained. One study
[18] was discarded for insufficient data (although we
tried to contact the authors to query the data), two
[19,20] were discarded as being studies on leukoplakia.
As shown in table 1, 21 case-control studies finally met
our criteria for inclusion [2,3,7,21-38]. 21 studies were
identified for the CYP2E1-PstI/RsaI polymorphism,
including a total of 4951 cases and 5995 controls, and
for the DraI polymorphism 9 studies were identified
covering a total of 2510 cases and 2162 controls. The
detailed characteristics of these studies are summarized
in table 1.
Meta-analysis results
CYP2E1-PstI/RsaI polymorphism
Our meta-analysis gave an overall OR of 1.96 (95% CI:
1.33-2.90, P < 0.001, PQ = 0.87) for head and neck can-
cer risk among c2 homozygotes of CYP2E1 RsaI/PstI
polymorphism compared with the wild type. However,
no other genetic model gave statistically significant
results.
When stratifying for ethnicity, c2 homozygotes were
significantly associated with HNSCC in Asian popula-
tions with an OR of 2.08(95% CI: 1.34-3.23, P < 0.001,
PQ = 0.52) among homozygotes (c2c2 versus c1c1). On
the other hand, no such association was detected in
Caucasian populations (p > 0.05 for all models). When
studies were stratified for study quality, an overall OR of
1.81 (95% CI: 1.13-2.89, P = 0.013, PQ = 0.92) for c2
homozygotes emerged for the high-quality scored stu-
dies. These positive associations were also present
among low-quality scored studies. Data on genotypes of
the PstI/RsaI polymorphism among cases and controls
stratified by smoking were available in five studies and
by alcohol consumption in four studies. The results of
the stratified meta-analyses according to smoking status
and alcohol consumption are shown in Table 2. The
overall ORs appeared similar in each subgroup in all
three genetic models.
CYP2E1-DraI polymorphism
We also carried out a comprehensive meta-analysis of
CYP2E1 DraI polymorphisms for each ethnic group and
for the different quality grades of studies under various
genetic models (Table 3). The overall OR of head and
neck cancer was 1.56(95% CI: 1.06-2.27, P = 0.021, PQ =
0.37) for homozygotes compared with wild genotype,
but no association was observed between T7632A and
head and neck cancer using other genetic models.
After stratification for ethnicity, we observed an OR of
1.99(95% CI: 1.22-3.24, P = 0.006, P Q =0 . 7 9 )f o rt h e
DraI polymorphism in Asian populations among homo-
zygotes (AA versus TT), whereas no such association
was observed in Caucasian populations. After stratifica-
tion for study quality, an overall OR of 2.36 (95% CI:
1.20-4.63, P = 0.012, PQ = 0.45) for homozygotes
emerged for the low-quality scored studies but no such
association was observed among high-quality studies
(Table 3).
Sensitivity analyses and Publication bias
Most studies indicated that the frequency distributions
of genotypes in the controls were consistent with
Hardy-Weinberg equilibrium (HWE), whereas deviations
from HWE were observed in three studies of the PstI/
RsaI polymorphism [21,28,30]. However, the corre-
sponding pooled ORs were not substantially altered
whether or not these studies were included (Data not
shown). In addition, sensitivity analysis indicated that no
single study influenced the pooled OR qualitatively, sug-
gesting that the results of this meta-analysis are stable.
Begger’s funnel plot and Egger’s test were used to
assess publication bias. The shape of the funnel plots
was symmetrical (Additional file 1). The Egger test pro-
vided evidence that there was no publication bias
among the studies included (p > 0.05, for all).
Discussion
In the present meta-analysis, we examined the associa-
tion between two widely studied CYP2E1 polymorphisms
Figure 1 Study selection process.
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found that the variant homozygote of the CYP2E1 PstI/
RsaI polymorphism was significantly associated with can-
cer risk in the overall comparisons, compared with the
wild homozygote. We also observed a significant associa-
tion between the CYP2E1 DraI polymorphism and cancer
risk for homozygote in the overall comparisons.
As for the PstI/RsaI polymorphism of CYP2E1,o u r
result showed a significantly high cancer risk for the c2
homozygote in Asian populations, with no such associa-
tion being found among Caucasian population under
any of the three genetic models. Ethnic differences may
attribute to these different results, since the distributions
of the less common c2 allele were different between var-
ious races, with a prevalence of ~25-50% and 5-10%
among Asians and Caucasians, respectively [39]. The c2
variant allele frequency did reach a statistically signifi-
cant level among Asians, while in the Caucasian popula-
tions, the lack of significant association might be
explained by the substantially lower statistical power
caused by the lower prevalence of CYP2E1 c2 allele
(5-10% against 25-50% for Asians).
CYP2E1 is presumed to confer susceptibility to
HNSCC by metabolizing carcinogens but, unfortunately,
few of the studies explored the interaction between the
CYP2E1 genotype and smoking habits or alcohol con-
sumption. This may be due to the low statistical power
of the individual studies to detect such interactions; but
all the studies which collected these data were utilized
for this meta-analysis. The stratified meta-analyses of all
the data on the PstI/RsaI genotype and smoking habits
or alcohol consumption with respect to head and neck
cancer risk produced no statistically significant results.
These results suggest that when the environmental and
genetic risk factors are both present, the combined
effect on head and neck cancer seems to be no longer
than additive of the separate effects. However, we can-
not ignore the fact that owing to the low prevalence of
c2 homozygotes in each study, even when data are
pooled, the statistical power to detect an interaction
remains low.
In addition, the DraI polymorphism was associated
with an increased cancer risk among Asians but not
among Caucasians, suggesting an ethnic difference in
terms of genetic and environmental factors [40]. How-
ever, only two studies of the DraI polymorphisms used
Asian population data and it is therefore probable that
the observed ethnic differences were simply due to
chance, given that studies with small sample size may
have insufficient statistical power to detect a slight
Table 1 Demography of the combined studies
Author, year Polymorphism Ethnicity Cases Controls Genotype distribution in controls
PstI/RsaI DraI
c1c1 c1c2 c2c2 TT TA AA
Olivieri et al.,2009 [2] PstI/RsaI Brazilian 153 145 105 16 0 / / /
Ruwali et al.,2009 [3] PstI/RsaI, DraI Indian 350 350 343 7 0 253 94 3
Bouchardy et al.,2000 [7] PstI/RsaI, DraI French Caucasians 250 172 164 8 0 151 20 1
Lucas et al.,1996 [21] PstI/RsaI, DraI French Caucasians 96 460 248 11 1 368 86 6
Hildesheim et al.,1997 [22] PstI/RsaI, DraI Taiwanese 364 320 198 113 9 183 123 14
Hung et al.,1997 [23] PstI/RsaI Taiwanese 41 122 76 42 4 / / /
González et al.,1998 [24] PstI/RsaI Spaish 75 200 179 21 0 / / /
Matthia et al.,1998 [25] PstI/RsaI, DraI German Caucasians 398 219 165 10 0 102 17 2
Morita et al.,1999 [26] PstI/RsaI Japanese 145 164 105 52 7 / / /
Katoh et al.,1999 [27] PstI/RsaI Japanese 92 146 95 45 7 / / /
Kongruttanachok et al.,2001 [28] PstI/RsaI Thai 217 297 189 103 5 / / /
Liu et al., 2001 [29] PstI/RsaI American 174 399 384 15 0 / / /
Neuhaus et al.,2004 [30] PstI/RsaI, DraI German 312 299 282 13 2 196 39 1
Li et al.,2005 [31] PstI/RsaI White American 724 1226 1137 86 3 / / /
Gajecka et al.,2005 [32] PstI/RsaI Poland Caucasians 289 316 305 18 0 / / /
Sugimura et al.,2006 [33] PstI/RsaI, DraI Japanese 122 241 164 70 7 126 97 18
Gattáet al.,2006 [34] PstI/RsaI Brazilian 103 102 96 6 0 / / /
Marques et al.,2006 [35] PstI/RsaI Brazilian 231 212 187 25 0 / / /
Soya et al.,2008 [36] PstI/RsaI, DraI Indian 408 220 212 8 0 145 65 10
Shama et al., 2008 [37] PstI/RsaI White American 197 416 364 39 0 / / /
Boccia et al.,2008 [38] PstI/RsaI, DraI Italian 210 245 228 15 1 224 19 1
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Sub-grouped studies Genetic model No.of Studies No.Cases/No.Controls Test of association Test of heterogeneity
OR (95% CI) P Q P Q I
2
Overall c2 carriers vs. wild 21 4892/5995 1.02(0.90-1.17) 0.68 31.37 0.05 36.26
c2 homozygotes vs. wild 17 3920/5008 1.96(1.33-2.90) <0.001 9.84 0.87 0
Dominant 21 4892/5995 1.08(0.95-1.22) 0.23 30.68 0.06 34.81
Asians c2 carriers vs. wild 6 981/1291 1.03(0.86-1.24) 0.69 5.95 0.31 16.01
c2 homozygotes vs. wild 6 981/1291 2.08(1.34-3.23) <0.001 4.17 0.52 0
Dominant 6 981/1291 1.12(0.94-1.33) 0.18 4.76 0.44 0
Caucasians c2 carriers vs. wild 15 3911/4704 1.07(0.82-1.40) 0.57 25.40 0.03 44.89
c2 homozygotes vs. wild 11 2939/3717 1.58(0.68-3.68) 0.28 5.35 0.86 0
Dominant 15 3911/4704 1.03(0.86-1.24) 0.49 25.49 0.03 45.09
High quality c2 carriers vs. wild 16 3914/4688 1.08(0.86-1.35) 0.48 26.49 0.033 43.38
c2 homozygotes vs. wild 13 3173/3913 1.81(1.13-2.89) 0.013 5.76 0.92 0
Dominant 16 3914/4688 1.11(0.90-1.37) 0.29 24.09 0.064 37.74
Low quality c2 carriers vs. wild 5 978/1307 1.07(0.84-1.36) 0.57 4.71 0.31 15.11
c2 homozygotes vs. wild 4 747/1095 2.36(1.16-4.79) 0.017 3.70 0.29 19.04
Dominant 5 978/1307 1.12(0.81-1.55) 0.46 6.38 0.17 37.39
Ever-smokers c2 carriers vs. wild 5 1173/831 0.62(0.34-1.12) 0.11 8.67 0.07 53.88
c2 homozygotes vs. wild 2 385/325 0.47(0.15-1.47) 0.19 0.10 0.74 0
Dominant 5 1173/831 0.61(0.33-1.11) 0.10 8.93 0.063 55.19
Never-smokers c2 carriers vs. wild 4 549/677 1.40(0.93-2.11) 0.09 0.44 0.93 0
c2 homozygotes vs. wild 3 441/431 3.25(0.48-21.70) 0.22 3.66 0.16 45.43
Dominant 4 549/677 1.45(0.98-2.16) 0.06 1.19 0.75 0
Alcohol- drinkers c2 carriers vs. wild 4 565/467 1.12(0.51-2.43) 0.76 8.39 0.039 64.26
c2 homozygotes vs. wild 2 198/296 1.48(0.34-6.44) 0.59 0.83 0.36 0
Dominant 4 565/467 1.11(0.53-2.29) 0.77 7.58 0.055 60.43
Non-drinkers c2 carriers vs. wild 3 653/883 0.92(0.64-1.33) 0.69 1.31 0.51 0
c2 homozygotes vs. wild 2 443/370 2.22(0.93-5.30) 0.07 0.004 0.94 0
Dominant 3 653/883 1.07(0.76-1.52) 0.67 1.08 0.58 0
Table 3 Stratified analysis of the CYP2E1 DraI polymorphism and HNSCC
Sub-grouped studies Genetic model No.of Studies No.Cases/No.Controls Test of association Test of heterogeneity
OR (95% CI) P Q P Q I
2
Overall AT vs. TT 9 2407/2126 1.15(0.90-1.47) 0.25 19.92 0.011 59.84
AA vs. TT 9 2407/2126 1.56(1.06-2.27) 0.021 8.62 0.37 7.21
Dominant 9 2407/2126 1.18(0.94-1.49) 0.13 18.81 0.016 57.47
Asians AT vs. TT 2 486/561 0.92(0.70-1.19) 0.53 0.13 0.71 0
AA vs. TT 2 486/561 1.99(1.22-3.24) 0.006 0.067 0.79 0
Dominant 2 486/561 1.04(0.81-1.34) 0.72 0.37 0.53 0
Caucasians AT vs. TT 7 1921/1601 1.24(0.92-1.66) 0.15 14.61 0.02 58.95
AA vs. TT 7 1921/1601 1.08(0.59-1.97) 0.78 6.18 0.40 2.98
Dominant 7 1921/1601 1.22(0.90-1.65) 0.18 16.29 0.01 63.17
High quality AT vs. TT 7 2189/1663 1.12(0.83-1.51) 0.43 18.33 0.005 67.27
AA vs. TT 7 2189/1663 1.28(0.81-2.03) 0.28 5.89 0.43 0
Dominant 7 2189/1663 1.13(0.85-1.49) 0.38 17.11 0.009 64.93
Low quality AT vs. TT 2 218/499 1.19(0.82-1.72) 0.35 1.59 0.20 37.10
AA vs. TT 2 218/499 2.36(1.20-4.63) 0.012 0.56 0.45 0
Dominant 2 218/499 1.35(0.95-1.92) 0.085 1.25 0.26 20.00
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f u r t h e rv a l i d a t ee t h n i cd i f f e rences in the effect of DraI
polymorphisms on cancer risk, especially in Asian
populations.
Currently, the mechanism whereby the rare allele of
the RsaI/PstI and DraI polymorphisms increases the risk
of head and neck cancer risk are still not clear. CYP2E1
is a phase I enzyme, which plays an essential role in the
metabolic activation of low molecular weight com-
pounds and pro-carcinogens such as N-nitrosamines,
benzene, and halogenated hydrocarbons. There is strong
evidence from in vitro studies suggesting that the rare
allele of the RsaI/PstI polymorphisms in the CYP2E1
gene probably confers a higher risk of HNSCC suscept-
ibility by increasing transcriptional and enzyme activity
[6]. Thus, the c2/c2 genotypes may be more liable to
metabolically activate mutagens and carcinogens. As for
the rare allele of the DraI polymorphism of the CYP2E1
gene, in vitro expression studies indicate that it is asso-
ciated with increased transcriptional activity [9]. The
AA genotypes may therefore have more ability to meta-
bolize mutagens and pro-carcinogens.
Some limitations should be considered when inter-
preting our results, in addition to those inherited from
the meta-analysis. First, our results are based on unad-
justed estimates, whereas adjustments for factors such
as age and sex would produce a more precise analysis.
The lack of this kind of information may cause serious
confounding bias. Further large and well-designed stu-
dies need to be performed to further confirm all these
results. Secondly, the subgroup meta-analyses dealing
with interactions between the CYP2E1 genotype and
smoking habits/alcohol consumption are based on the
small number of studies where such information is
available. Nevertheless the number of subjects included
in this part of the analysis comprised the largest sample
of all. Third, the quality score of the individual studies
included in our meta-analysis was assessed on the basis
of trying to minimize the potential for selection bias,
misclassification related to exposure, collection of data
on potential confounders and method of statistical ana-
lysis. No validated quality assessment system currently
exists, and it is evident that our quality scale has a sub-
jective component.
Conclusions
In summary, this may be the first systematic and com-
prehensive meta-analysis of CYP2E1 and HNSCC. Our
results indicate that the CYP2E1-PstI/RsaI and DraI
polymorphisms may be a risk factor for head and neck
cancer in Asian populations, and particularly for indivi-
dual homozygotes for the unfavourable gene variant.
However additional large studies are needed to validate
our findings. Future studies should use standardized
unbiased genotyping methods as well as homogeneous
cancer patients and well-matched controls.
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